Patents by Inventor Mikkel Wandahl Pedersen

Mikkel Wandahl Pedersen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • COMBINATION THERAPIES TARGETING PD-1, TIM-3, AND LAG-3
    Publication number: 20240270848
    Abstract: This invention relates to combination therapies targeting two or all of PD-1, TIM-3, and LAG-3 using antibodies specific for these targets in patients who are in need of enhanced immunity. Also included in the invention are compositions useful in the therapies. The therapies are useful in treating diseases such as cancers.
    Type: Application
    Filed: February 16, 2024
    Publication date: August 15, 2024
    Applicant: LES LABORATOIRES SERVIER
    Inventors: Trine Lindsted, Michael Monrad Grandal, Eva Maria Carlsen Melander, Camilla Fröhlich, Mikkel Wandahl Pedersen, Michael Kragh, Johan Lantto, Monika Gad, Ivan David Horak
  • Combination therapies targeting PD-1, TIM-3, and LAG-3
    Patent number: 11939380
    Abstract: This disclosure relates to combination therapies targeting two or all of PD-1, TIM-3, and LAG-3 using antibodies specific for these targets in patients who are in need of enhanced immunity. Also included in the disclosure are compositions useful in the therapies. The therapies are useful in treating diseases such as cancers.
    Type: Grant
    Filed: April 5, 2018
    Date of Patent: March 26, 2024
    Assignee: LES LABORATOIRES SERVIER
    Inventors: Trine Lindsted, Michael Monrad Grandal, Eva Maria Carlsen Melander, Camilla Fröhlich, Mikkel Wandahl Pedersen, Michael Kragh, Johan Lantto, Monika Gad, Ivan David Horak
  • ANTI-LAG-3 ANTIBODIES AND COMPOSITIONS
    Publication number: 20240052032
    Abstract: This invention relates to anti-LAG-3 antibodies and methods of using them in treating diseases and conditions that benefit from modulating LAG-3 activity, such as cancer.
    Type: Application
    Filed: October 19, 2023
    Publication date: February 15, 2024
    Inventors: Michael Monrad GRANDAL, Vikram Kjøller BHATIA, Torben GJETTING, Camilla FRÖHLICH, Gunther Roland GALLER, Michael KRAGH, Ivan David HORAK, Thomas BOUQUIN, Mikkel Wandahl PEDERSEN
  • Anti-lag-3 antibodies and compositions
    Patent number: 11834503
    Abstract: This invention relates to anti-LAG-3 antibodies and methods of using them in treating diseases and conditions that benefit from modulating LAG-3 activity, e.g., cancer.
    Type: Grant
    Filed: June 7, 2022
    Date of Patent: December 5, 2023
    Assignee: CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD.
    Inventors: Michael Monrad Grandal, Vikram Kjøller Bhatia, Torben Gjetting, Camilla Fröhlich, Gunther Roland Galler, Michael Kragh, Ivan David Horak, Thomas Bouquin, Mikkel Wandahl Pedersen
  • ANTI-TIM-3 ANTIBODIES AND COMPOSITIONS
    Publication number: 20230105714
    Abstract: This invention relates to anti-TIM-3 antibodies and antibody compositions and their use in enhancing immunity in a patient, e.g., to treat cancer.
    Type: Application
    Filed: May 11, 2022
    Publication date: April 6, 2023
    Applicant: SYMPHOGEN A/S
    Inventors: Trine LINDSTED, Torben GJETTING, Gunther Roland GALLER, Monika GAD, Michael Monrad GRANDAL, Klaus KOEFOED, Michael KRAGH, Ivan David HORAK, Thomas BOUQUIN, Mikkel Wandahl PEDERSEN
  • COMBINATION THERAPIES TARGETING PD-1, TIM-3, AND LAG-3
    Publication number: 20220380470
    Abstract: This invention relates to combination therapies targeting two or all of PD-1, TIM-3, and LAG-3 using antibodies specific for these targets in patients who are in need of enhanced immunity. Also included in the invention are compositions useful in the therapies. The therapies are useful in treating diseases such as cancers.
    Type: Application
    Filed: June 7, 2022
    Publication date: December 1, 2022
    Applicant: SYMPHOGEN A/S
    Inventors: Trine Lindsted, Michael Monrad Grandal, Eva Maria Carlsen Melander, Camilla Fröhlich, Mikkel Wandahl Pedersen, Michael Kragh, Johan Lantto, Monika Gad, Ivan David Horak
  • ANTI-LAG-3 ANTIBODIES AND COMPOSITIONS
    Publication number: 20220363757
    Abstract: This invention relates to anti-LAG-3 antibodies and methods of using them in treating diseases and conditions that benefit from modulating LAG-3 activity, e.g., cancer.
    Type: Application
    Filed: June 7, 2022
    Publication date: November 17, 2022
    Applicant: SYMPHOGEN A/S
    Inventors: Michael Monrad GRANDAL, Vikram Kjøller BHATIA, Torben GJETTING, Camilla FRÖHLICH, Gunther Roland GALLER, Michael KRAGH, Ivan David HORAK, Thomas BOUQUIN, Mikkel Wandahl PEDERSEN
  • Anti-TIM-3 antibodies and compositions
    Patent number: 11390674
    Abstract: This invention relates to anti-TIM-3 antibodies and antibody compositions and their use in enhancing immunity in a patient, e.g., to treat cancer.
    Type: Grant
    Filed: April 11, 2017
    Date of Patent: July 19, 2022
    Assignee: Symphogen A/S
    Inventors: Trine Lindsted, Torben Gjetting, Gunther Roland Galler, Monika Gad, Michael Monrad Grandal, Klaus Koefoed, Michael Kragh, Ivan David Horak, Thomas Bouquin, Mikkel Wandahl Pedersen
  • Anti-LAG-3 antibodies and compositions
    Patent number: 11390676
    Abstract: This invention relates to anti-LAG-3 antibodies and methods of using them in treating diseases and conditions that benefit from modulating LAG-3 activity, e.g., cancer.
    Type: Grant
    Filed: October 13, 2017
    Date of Patent: July 19, 2022
    Assignee: Symphogen A/S
    Inventors: Michael Monrad Grandal, Vikram Kjøller Bhatia, Torben Gjetting, Camilla Fröhlich, Gunther Roland Galler, Michael Kragh, Ivan David Horak, Thomas Bouquin, Mikkel Wandahl Pedersen
  • ANTI-LAG-3 ANTIBODIES AND COMPOSITIONS
    Publication number: 20220056126
    Abstract: This invention relates to anti-LAG-3 antibodies and methods of using them in treating diseases and conditions that benefit from modulating LAG-3 activity, e.g., cancer.
    Type: Application
    Filed: October 13, 2017
    Publication date: February 24, 2022
    Applicant: SYMPHOGEN A/S
    Inventors: Michael Monrad GRANDAL, Vikram Kjøller BHATIA, Torben GJETTING, Camilla FRÖHLICH, Gunther Roland GALLER, Michael KRAGH, Ivan David HORAK, Thomas BOUQUIN, Mikkel Wandahl PEDERSEN
  • ANTI-FLT3 ANTIBODIES AND COMPOSITIONS
    Publication number: 20210317216
    Abstract: This invention relates to anti-FLT3 antibodies and methods of using them in enhancing immunity in a patient in need thereof and in treating cancer.
    Type: Application
    Filed: April 14, 2021
    Publication date: October 14, 2021
    Applicant: SYMPHOGEN A/S
    Inventors: Trine Lindsted, Maria Carlsen Melander, Matteo Riva, Mikkel Wandahl Pedersen, Randi Westh HANSEN
  • ANTI-CD40 ANTIBODIES AND COMPOSITIONS
    Publication number: 20210214454
    Abstract: This invention relates to anti-CD40 antibodies and methods of using them in treating diseases and conditions related to CD40 activity, e.g., cancer.
    Type: Application
    Filed: January 8, 2021
    Publication date: July 15, 2021
    Applicant: SYMPHOGEN A/S
    Inventors: Anton WILLER, Trine LINDSTED, Klaus KOEFOED, Mikkel Wandahl PEDERSEN, Lise Camilla FRÖHLICH
  • COMBINATION THERAPIES TARGETING PD-1, TIM-3, AND LAG-3
    Publication number: 20200407444
    Abstract: This disclosure relates to combination therapies targeting two or all of PD-1, TIM-3, and LAG-3 using antibodies specific for these targets in patients who are in need of enhanced immunity. Also included in the disclosure are compositions useful in the therapies. The therapies are useful in treating diseases such as cancers.
    Type: Application
    Filed: April 5, 2018
    Publication date: December 31, 2020
    Applicant: SYMPHOGEN A/S
    Inventors: Trine Lindsted, Michael Monrad Grandal, Eva Maria Carlsen Melander, Camilla Fröhlich, Mikkel Wandahl Pedersen, Michael Kragh, Johan Lantto, Monika Gad, Ivan David Horak
  • Anti-MET antibodies and compositions
    Patent number: 10450376
    Abstract: The present invention relates to novel recombinant antibodies directed against human MET (c-MET), as well as compositions comprising mixtures of at least two of said antibodies and use of the antibodies and antibody compositions for treatment of MET-mediated disorders such as cancer.
    Type: Grant
    Filed: September 15, 2015
    Date of Patent: October 22, 2019
    Assignee: Symphogen A/S
    Inventors: Thomas Bouquin, Mikkel Wandahl Pedersen, Helle Jane Jacobsen, Thomas Tuxen Poulsen, Michael Monrad Grandal, Klaus Koefoed, Michael Kragh, Karsten Wessel Eriksen, Paolo Conrotto
  • ANTI-TIM-3 ANTIBODIES AND COMPOSITIONS
    Publication number: 20190276531
    Abstract: This invention relates to anti-TIM-3 antibodies and antibody compositions and their use in enhancing immunity in a patient, e.g., to treat cancer.
    Type: Application
    Filed: April 11, 2017
    Publication date: September 12, 2019
    Applicant: SYMPHOGEN A/S
    Inventors: Trine LINDSTED, Torben GJETTING, Gunther Roland GALLER, Monika GAD, Michael Monrad GRANDAL, Klaus KOEFOED, Michael KRAGH, Ivan David HORAK, Thomas BOUQUIN, Mikkel Wandahl PEDERSEN
  • Pan-HER antibody composition
    Patent number: 10221246
    Abstract: The present invention is directed to improved therapeutics against receptors within the EGFR/ErbB/HER family that more broadly interfere with multiple members of the HER family (pan-HER inhibition). More particularly, the invention is directed to the use of antibody compositions for human cancer therapy. In vitro studies have shown that the antibody compositions of the invention targeting multiple HER family receptors are superior to antibody compositions targeting only one HER family receptor.
    Type: Grant
    Filed: November 28, 2016
    Date of Patent: March 5, 2019
    Assignee: Symphogen A/S
    Inventors: Mikkel Wandahl Pedersen, Ida K. Christensen, Johan Lantto, Helle Jacobsen, Michael Kragh
  • HUMANIZED PAN-HER ANTIBODY COMPOSITIONS
    Publication number: 20180344846
    Abstract: The invention relates to humanized recombinant antibodies targeting the EGFR family receptors EGFR, HER2 and HER3, compositions comprising at least one humanized anti-EGFR antibody, at least one humanized anti-HER2 antibody and at least one humanized anti-HER3 antibody, and use of the antibody compositions for treatment of cancer. The invention also relates to the use of antibodies targeting multiple EGFR-family receptors to treat cancer (e.g., pancreatic cancer) and cancer that has acquired resistance to previous therapies.
    Type: Application
    Filed: August 8, 2018
    Publication date: December 6, 2018
    Applicant: Symphogen A/S
    Inventors: Johan Lantto, Kim Vilbour Andersen, Peter Sejer Andersen, Magnus Strandh, Klaus Koefoed, Lars Søgaard Nielsen, Mikkel Wandahl Pedersen, Helle Jacobsen, Michael Kragh, Ida Kjaer, Thomas Tuxen Poulsen
  • ANTI-MET ANTIBODIES AND COMPOSITIONS
    Publication number: 20180327500
    Abstract: The present invention relates to novel recombinant antibodies directed against human MET (c-MET), as well as compositions comprising mixtures of at least two of said antibodies and use of the antibodies and antibody compositions for treatment of MET-mediated disorders such as cancer.
    Type: Application
    Filed: September 15, 2015
    Publication date: November 15, 2018
    Inventors: Thomas Bouquin, Mikkel Wandahl Pedersen, Helle Jane Jacobsen, Thomas Tuxen Poulsen, Michael Monrad Grandal, Klaus Koefoed, Michael Kragh, Karsten Wessel Eriksen, Paolo Conrotto
  • Methods for treating cancer by administering humanized pan-HER antibody compositions
    Patent number: 10058610
    Abstract: The invention relates to humanized recombinant antibodies targeting the EGFR family receptors EGFR, HER2 and HER3, compositions comprising at least one humanized anti-EGFR antibody, at least one humanized anti-HER2 antibody and at least one humanized anti-HER3 antibody, and use of the antibody compositions for treatment of cancer. The invention also relates to the use of antibodies targeting multiple EGFR-family receptors to treat cancer (e.g., pancreatic cancer) and cancer that has acquired resistance to previous therapies.
    Type: Grant
    Filed: November 14, 2016
    Date of Patent: August 28, 2018
    Assignee: Symphogen A/S
    Inventors: Johan Lantto, Kim Vilbour Andersen, Peter Sejer Andersen, Magnus Strandh, Klaus Koefoed, Lars Søgaard Nielsen, Mikkel Wandahl Pedersen, Helle Jacobsen, Michael Kragh, Ida Kjaer, Thomas Tuxen Poulsen
  • HUMANIZED PAN-HER ANTIBODY COMPOSITIONS
    Publication number: 20170165365
    Abstract: The invention relates to humanized recombinant antibodies targeting the EGFR family receptors EGFR, HER2 and HER3, compositions comprising at least one humanized anti-EGFR antibody, at least one humanized anti-HER2 antibody and at least one humanized anti-HER3 antibody, and use of the antibody compositions for treatment of cancer. The invention also relates to the use of antibodies targeting multiple EGFR-family receptors to treat cancer (e.g., pancreatic cancer) and cancer that has acquired resistance to previous therapies.
    Type: Application
    Filed: November 14, 2016
    Publication date: June 15, 2017
    Inventors: Johan Lantto, Kim Vilbour Andersen, Peter Sejer Andersen, Magnus Strandh, Klaus Koefoed, Lars Søgaard Nielsen, Mikkel Wandahl Pedersen, Helle Jacobsen, Michael Kragh, Ida Kjaer, Thomas Tuxen Poulsen